Showing 141-150 of 3938 results for "".
Dr. Joel Schlessinger discusses Botox treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-joel-schlessinger-discusses-botox-treatments/19321/Joel Schlessinger, MD takes you through a BOTOX treatment step-by-step, explaining each piece of the process. The video begins with a quick description of BOTOX, Dysport and Xeomin before moving on to show the process of taking pre-treatment photos and performing a consultation. Dr. Schlessinger theJAK Inhibitors in Hidradenitis Suppurativa: A Systematic Review
https://practicaldermatology.com/topics/feature/jak-inhibitors-in-hidradenitis-suppurativa-a-systematic-review/29887/Hidradenitis suppurativa (HS) is a chronic, disfiguring, debilitating, inflammatory disorder that is characterized by inflammatory nodules, abscesses, fistulae/ sinus tracts, and scarring to the axilla, inframammary folds, and groin.Home-Use Laser and Light Devices: Just What the Doctor Ordered
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/home-use-laser-and-light-devices-just-what-the-doctor-ordered/23335/Laser and light-based devices are more at home than ever as lightweight LEDs, wearable technology, and “smart” apps support adherence and enhance efficacy.Vitiligo: Oral and Topical JAKs Show Promise
https://practicaldermatology.com/topics/pigmentary-disorders/vitiligo-oral-and-topical-jaks-show-promise/23316/Early studies offer some hope for emerging therapies for repigmentation.Technology Solutions: Q&A With Nextech's Dr. Jason Handza
https://practicaldermatology.com/topics/practice-management/technology-solutions-q-nextechs-dr-jason-handza/28649/Nextech this year introduced Nextech RCM Professional Billing Services, an addition to their practice management software suite. This solution simplifies insurance billing complexities, helping practices reduce administrative burdens and enhance financial performance through optimized cash flow.Bimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.The Excoriated and Bleeding Edge: Updates in Eczema for the Clinician
https://practicaldermatology.com/topics/general-topics/the-excoriated-and-bleeding-edge-updates-in-eczema-for-the-clinician/21469/Atopic dermatitis continues to present treatment challenges, but a steady juggling of four main components—moisturization, antibiotics, anti-inflammatory, and antipruritics— help to maximize control of the disease.Lose Your Inhibitions: Expanding Use of JAK Inhibitors
https://practicaldermatology.com/topics/atopic-dermatitis/lose-your-inhibitions-expanding-use-of-jak-inhibitors/23910/Despite data on safety concerns, dermatologists and patients see benefits.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Jejunal Trichobezoar in a 3-year-old Boy; Practice Path MD Pro Tip: Architects
https://practicaldermatology.com/youngmd-connect/resident-resource-center/jejunal-trichobezoar-in-a-3-year-old-boy-practice-path-md-pro-tip-architects/20697/